Roche
Roche signs deal with Skyhawk over molecules that modulate RNA splicing
July 17, 2019Research and Development Genentech, Roche, Skyhawk, drug development, rna splicing
Roche’s Genentech unit has signed a deal with Massachusetts-based firm Skyhawk Therapeutics to develop and commercialise small molecules that modulate …
Genentech signs $1 billion deal with Sosei over GCPRs
July 17, 2019Research and Development Genentech, Roche, gcprs, pharma, sosei
Roche’s Genentech has entered into a partnership with Sosei Heptares to develop small molecules and biologics that G protein-coupled receptor …
Roche unveils wave of strong Hemlibra data in haemophilia A with or without factor VIII inhibitors
July 9, 2019Manufacturing and Production, Research and Development Roche, haemophilia, pharma
Roche revealed a swathe of new data on Hemlibra (emicizumab) at the International Society on Thrombosis and Haemostasis (ISTH) 2019 …
Roche’s Xofluza proves non-inferior to Tamiflu in children with flu
July 3, 2019Research and Development Roche, Tamiflu, flu, pharma
Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its …
Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer
July 2, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …
Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours
June 18, 2019Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma
Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …
Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma
June 11, 2019Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma
Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …
Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents
May 17, 2019Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …
FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia
May 16, 2019Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer
March 20, 2019Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …
FDA puts multiple myeloma trial on hold after patient deaths
March 20, 2019Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …
Roche scores two EU approvals in haemophilia and rare autoimmune disease
March 15, 2019Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases
The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …
Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors
March 14, 2019Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma
Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
